ClinicalTrials.gg
CompletedNCT05555706Updated Apr 15, 2025

Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

A Phase 2/3 interventional study of B013+Nab-Paclitaxel in Triple Negative Breast Cancer (TNBC), sponsored by Shanghai Jiaolian Drug Research and Development Co., Ltd. Completed at 13 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-15.

Sponsored by Shanghai Jiaolian Drug Research and Development Co., Ltd · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies testing Albumin-Bound Paclitaxel in Triple Negative Breast Neoplasms — 7 open to participants now, 9 under way, none of them phase 3. Albumin-Bound Paclitaxel · Triple Negative Breast Neoplasms.

Enrollment
14th of 25
62 · median 64
Started
2022
with 1 other
Phase 2/3
2 of 25
none open now
Registered
20th of 25
by date

Among the 25 studies testing Albumin-Bound Paclitaxel in Triple Negative Breast Neoplasms, this one is the 14th largest by enrollment, is one of 2 that started in 2022, is one of 2 in phase 2/3, and was the 20th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

7 of the 25 studies testing Albumin-Bound Paclitaxel in Triple Negative Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About Albumin-Bound Paclitaxel

Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing Albumin-Bound Paclitaxel in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

This Phase II/III study assessed the efficacy, safety, pharmacokinetics, and immunogenicity of B013 administered with nab-paclitaxel in participants with locally advanced or metastatic triple negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).

03

Conditions studied

  • Triple Negative Breast Cancer (TNBC)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women or men aged 18 -75 years
  2. Locally advanced or triple negative breast cancer (TNBC)
  3. No prior chemotherapy or targeted systemic therapy for inoperable locally advanced or metastatic TNBC
  4. performance status of 0 or 1
  5. Patient must have measurable or evaluable disease as defined by v1.1. will be confirmed by radiographic imaging (CT or MRI)

Exclusion criteria

Exclusion Criteria:

  1. Previous treatment is eligible.
  2. Spinal cord compression not definitively treated with surgery and/or radiation prior to study entry
  3. Known central nervous system (CNS) disease
  4. Uncontrolled pleural effusion, pericardial effusion, or ascites Patients
  5. Uncontrolled tumor-related pain prior to study entry
  6. The patient has a history of another within 5 years prior to study entry, except adequately treated non-melanotic skin cancer, carcinoma in situ of the cervix or Papillary carcinoma of the thyroid
  7. Pregnancy or lactation
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    B013+ Nab-Paclitaxel

    B013 at a fixed dose of 600 milligrams via intravenous (IV) infusion on Days 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle. Nab-Paclitaxel 100 mg/m\^2 is administered weekly on Days 1, 8, 15 of each 28-day cycle.

    Drug: B013+Nab-Paclitaxel

Interventions

  • DrugB013+Nab-Paclitaxel

    Drug page: Albumin-Bound PaclitaxelStudies of Albumin-Bound PaclitaxelAlbumin-Bound Paclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    B013 at a fixed dose of 600 milligrams via intravenous (IV) infusion on Days 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle. Nab-Paclitaxel 100 mg/m\^2 is administered weekly on Days 1, 8, 15 of each 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)(phase Ⅱ)

    tumor response will be evaluated according to the Response Evaluation Criteria Solid Tumors (RECIST) criteria version 1.1.

    Time frame: Baseline up to approximately 18 months

  2. Progression-free survival (PFS)(IRC) (phase Ⅲ)

    from the start date of study treatment to the date of progression disease or death , whichever occurred first.

    Time frame: Baseline up to approximately 18 months

Secondary outcomes

  1. Disease control rate (DCR)

    DCR was defined as the percentage of patients who have achieved complete response, partial response and stable disease

    Time frame: 18 months

  2. Duration of remission (DOR)

    DOR was defined for participants who had an objective response as the time from the first occurrence of a documented unconfirmed response (CR or PR) to the date of disease progression per RECIST v1.1 or death from any cause

    Time frame: 18 months

  3. Time to Response (TTR)

    Defined as the interval from the start of study therapy to the first documentation of an objective response

    Time frame: 18 months

  4. Overall Survival (OS)

    Determination of the overall survival times of all patients

    Time frame: 3years

  5. Drug concentration in plasma

    Determination of drug concentration in plasma of all patients

    Time frame: 18 months

  6. Incidence of Treatment-Emergent Adverse Events

    Adverse event type, incidence, duration, correlation with study drug

    Time frame: 3years

07

Study locations

13 sites
  • Affiliated Cancer Hospital, Sun Yat-sen University
    Guangzhou, Guangdong 510060, China
  • Guangxi Medical University Cancer Hospital
    Nanning, Guangxi 530021, China
  • Hainan cancer Hospital
    Haikou, Hainan 570312, China
  • The First Affiliated Hospital of henan University of Science and Technoloy
    Luoyang, Henan 450062, China
  • Xiangyang Central Hospital
    Xiangyang, Hubei 441021, China
  • The Central Hospital of Yongzhou
    Yongzhou, Hunan 425002, China
  • Huai'an First People's Hospital
    Huai'an, Jiangsu 223300, China
  • Sichuan Cancer Hospital
    Chengdu, Sichuan 610041, China
  • The second people's hospital of neijiang
    Neijiang, Sichuan 641199, China
  • Yunnan Cancer Hospital
    Kunming, Yunnan 650118, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310005, China
  • Peking University Cancer Hospital
    Beijing, 100142, China
  • Tianjin medical university cancer institute&hospital
    Tianjin, 300060, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Sep 2024, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2022
First posted
Sep 27, 2022
StartActual
Dec 6, 2022
Primary completionActual
Sep 30, 2024
CompletionActual
Sep 30, 2024
Last update
Apr 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05555706
Lead sponsor
Shanghai Jiaolian Drug Research and Development Co., Ltd
Responsible party
Sponsor
First posted
Sep 27, 2022
Start date
Dec 6, 2022
Primary completion
Sep 30, 2024
Completion
Sep 30, 2024
Last update
Apr 15, 2025

Study contacts

Shusen Wang
principal investigator · Affiliated Cancer Hospital, Sun Yat-sen University
Huiping Li
principal investigator · Peking University Cancer Hospital & Institute

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albumin-Bound Paclitaxel

Start the discussion